Numerous SHP2-AIs have been described, and more than ten SHP2-AIs are now in clinical development for the treatment of cancers caused by aberrant RAS-MAPK activation, either as single agents or in combination with inhibitors of RTKs, KRAS, or MEK1/2 (36, 37). Here, MAP2K1 is linked to cancer.